Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

Abstract

The results of the current study confirm that CPT-11 plus celecoxib can be safely administered concurrently at full dose levels, and that this regimen has encouraging activity among heavily pretreated patients with recurrent MG.